Resource Center
Explore Resource Types
We have housed the technical documents (SDS, COAs, Manuals and more) in a dedicated section.
Explore all All Resources
Filters
Select resource types
Select products & services
Select solutions (2)
Active Filters (2)
Clear All
121 - 132 of 152 Results
Sort by:
Best Match
Application Note
Simultaneous measurement of chemokine/cytokine release and antibody-dependent cellular cytotoxicity upon binding with rituximab
Simultaneous detection of ADCC activity and release of chemokines and cytokines from activated NK cells is possible via the combined use of DELFIA TRF and AlphaLISA technologies.
Application Note
Evaluating the specificity of PD-1 and PD-L1 blocking antibodies using AlphaLISA human and mouse PD-1/PD-L1 binding kits
Find out how the AlphaLISA human/mouse PD-1/PD-L1 binding assays provide a fast, powerful, homogeneous platform for obtain binding potencies from potential novel drug candidates.
Application Note
Utilization of AlphaLISA technology to accurately detect asthma biomarkers in human serum
In this application note, AlphaLISA technology was used to quantify biomarker levels in serum samples, specifically Human IL-21, IL-33, and TNFα.
Application Note
Fc-Receptor binding ADCC assays utilizing AlphaLISA technology: Characterization of hIgGs and FcγRIIIa
This application note demonstrates how AlphaLISA assay can be used to determine the binding activity of human IgG Fc fragment to human FcγRIIIa and to study how other antibodies bind to FcγRIIIa.
Application Note
No-Wash IP1 assays are a powerful readout to characterize compounds modulating the FGFR signaling pathway in cancer drug research
This application note demonstrates that detecting the intracellular accumulation of IP1, mediated by FGFR-dependent activation of PLCγ1, can be a powerful alternative for characterizing compounds that modulate FGFR signaling in various cancer cell lines expressing FGFR1, FGFR2, and FGFR3.
Infographic
Addressing the challenges in modern biotherapeutic development
Explore next-generation approaches to enable the development and characterization of bispecific and multi-specific antibodies
Application Note
Protocol optimization for detection and quantification of membrane-bound proteins using AlphaLISA technology
AlphaLISA kits have the capability to assess hundreds of targets, including cytokines, proteins circulating in the blood, and cellular proteins.
Brochure
Biologics workflow solutions
Revvity can help you discover and develop high-quality biological drug products by streamlining the biologics workflow.
Product Note
Automated characterization of proteins and nucleic acids
Streamline your slab gel electrophoresis, while providing increased throughput and the data formats required for biotherapeutics and genomics workflows.
Literature - Publication Review
Current approaches to identify possible COVID-19 therapeutics
Current approaches to identify possible COVID-19 treatment strategies fall into one of three categories: Antivirals, antibodies, or protein-protein interaction inhibitors.
Whitepaper
An emerging therapeutic modality - RNA carves its path out of the paradigm
Learn more about several promising classes of RNA therapeutic, including RNAi, CRISPR, base editing, and mRNA vaccines, as well as the potential to combine RNA technologies with CAR-T.
Application Note
Streamlining the development of bispecific antibodies from expression to quality assessment with Revvity’s biotherapeutic workflow solutions
Expression and characterization of bispecific antibodies with a combination of CHOSOURCE TnT Transposon Technology and LabChip to streamline biotherapeutic workflows
Looking for technical documents?
Find the technical documents you need, ASAP, in our easy-to-search library.